Literature DB >> 11054722

Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension.

C Orte1, J M Polak, S G Haworth, M H Yacoub, N W Morrell.   

Abstract

The hypothesis for this study was that increased local expression of vascular angiotensin-converting enzyme (ACE) may contribute to the arterial remodelling which accompanies pulmonary hypertension, since angiotensin II (ANG II) is an important mediator of pulmonary vascular cell growth. The expression of ACE was studied by immunohistochemistry in paraffin-embedded lung sections from adults undergoing heart-lung transplantation for severe primary (n=6) and secondary (n=7) pulmonary arterial hypertension (PH), compared with age-matched controls (n=11). An antigen retrieval technique was used prior to incubating sections with the anti-ACE monoclonal antibody, CG2, or the endothelial marker, monoclonal anti-CD31. In control lungs, the highest level of ACE immunostaining was seen in the alveolar capillary endothelium, with less intense staining in small intra-acinar pulmonary arteries and relatively little staining in larger preacinar arteries. ACE immunostaining was virtually absent in lymphatics and veins. In both primary and secondary PH, there was an increase in ACE immunostaining in the endothelium of intra-acinar peripheral pulmonary arteries compared with control lungs, extending to the level of alveolar ducts, as confirmed by semi-quantitative analysis. The increase in endothelial ACE expression in the intra-acinar arteries of patients with primary and secondary PH is consistent with the hypothesis that locally increased production of ANG II may contribute to the process of pulmonary vascular remodelling. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11054722     DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH715>3.0.CO;2-Q

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  39 in total

Review 1.  New insights into the pathogenesis and treatment of primary pulmonary hypertension.

Authors:  N Rudarakanchana; R C Trembath; N W Morrell
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

Review 2.  Pulmonary Hypertension and ATP-Sensitive Potassium Channels.

Authors:  Conor McClenaghan; Kel Vin Woo; Colin G Nichols
Journal:  Hypertension       Date:  2019-05-28       Impact factor: 10.190

3.  Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer.

Authors:  Yoriko Yamazato; Anderson J Ferreira; Kwon-Ho Hong; Srinivas Sriramula; Joseph Francis; Masanobu Yamazato; Lihui Yuan; Chastity N Bradford; Vinayak Shenoy; Suk P Oh; Michael J Katovich; Mohan K Raizada
Journal:  Hypertension       Date:  2009-06-29       Impact factor: 10.190

4.  The renin-angiotensin system in pulmonary hypertension.

Authors:  Nicholas W Morrell; Kurt R Stenmark
Journal:  Am J Respir Crit Care Med       Date:  2013-05-15       Impact factor: 21.405

Review 5.  Neurohormonal activation and pharmacological inhibition in pulmonary arterial hypertension and related right ventricular failure.

Authors:  Pietro Ameri; Edoardo Bertero; Giovanni Meliota; Martino Cheli; Marco Canepa; Claudio Brunelli; Manrico Balbi
Journal:  Heart Fail Rev       Date:  2016-09       Impact factor: 4.214

6.  Protective effects of astragaloside IV against hypoxic pulmonary hypertension.

Authors:  Xiaozheng Zhang; Jun Chen; Pan Xu; Xin Tian
Journal:  Medchemcomm       Date:  2018-09-04       Impact factor: 3.597

7.  The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension.

Authors:  Vinayak Shenoy; Anderson J Ferreira; Yanfei Qi; Rodrigo A Fraga-Silva; Carlos Díez-Freire; Autumn Dooies; Joo Yun Jun; Srinivas Sriramula; Nithya Mariappan; Dorna Pourang; Changaram S Venugopal; Joseph Francis; Timothy Reudelhuber; Robson A Santos; Jawaharlal M Patel; Mohan K Raizada; Michael J Katovich
Journal:  Am J Respir Crit Care Med       Date:  2010-06-25       Impact factor: 21.405

8.  Human immunodeficiency virus transgenic rats exhibit pulmonary hypertension.

Authors:  Amie K Lund; Joann Lucero; Lindsay Herbert; Yushi Liu; Jay S Naik
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-06-17       Impact factor: 5.464

9.  NFATc3 mediates chronic hypoxia-induced pulmonary arterial remodeling with alpha-actin up-regulation.

Authors:  Sergio de Frutos; Rhyannon Spangler; Dominique Alò; Laura V González Bosc
Journal:  J Biol Chem       Date:  2007-04-02       Impact factor: 5.157

10.  Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis.

Authors:  E Bruce; V Shenoy; A Rathinasabapathy; A Espejo; A Horowitz; A Oswalt; J Francis; A Nair; T Unger; M K Raizada; U M Steckelings; C Sumners; M J Katovich
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.